Experiments in clinical samples have shown down-regulation of PART1 in biological samples obtained from patients with Alzheimer’s disease (Huaying et al., 2020), Parkinson’s disease (Chi et al., 2019) and preeclampsia (Peñailillo et al., 2022). The gene discussed is PART1; the disease is Parkinson disease.